Blood Biological Markers for Prediction of Escitalopram Response in Patients with Major Depressive Disorder: Preliminary Study
|Masato Yamana, Kiyokazu Atake, Asuka Katsuki, Hikaru Hori and Reiji Yoshimura*|
|Department of Psychiatry, University of Occupational and Environmental Health, Japan|
|*Corresponding Author :||Reiji Yoshimura
Department of Psychiatry, University of Occupational and Environmental Health
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka8078555, Japan
E-mail: [email protected]
|Received: February 10, 2016; Accepted: February 29, 2016; Published: March 03, 2016|
|Citation: Yamana M, Atake K, Katsuki A, Hori H, Yoshimura R (2016) Blood Biological Markers for Prediction of Escitalopram Response in Patients with Major Depressive Disorder: Preliminary Study. J Depress Anxiety 5:222. doi:10.4200/2167-1044.1000222|
|Copyright: © 2016 Yamana M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Introduction: Lots of studies have been performed to predict the response to antidepressants in patients with major depressive disorder. The findings were however controversial. Objective: The aim of the present study was to investigate the relationship between response to escitalopram and several peripheral biomarkers in major depressive disorder (MDD).
Material and Methods: Forty-eight MDD patients diagnosed by DSM-IV-TR were enrolled the study, and all were treated with escitalopram. The end-point of the study was 8 weeks after starting the treatment. Twenty-seven patients were completed the study. Their depressive symptoms were evaluated using the 17-items Hamilton Rating Scale for Depression (HAMD17). The patients whose HAMD17 reduced 50% or more at 8 weeks were defined as responders. The peripheral biomarkers were assayed with ELISA or high-performance liquid chromatography.
Results: Plasma 3-methoxy-4-hydroxyphenil glycol (MHPG) level at starting escitalopram in the responders were significantly higher than those in nonresponders (p = 0.0032). Any other factors were not different between the responders and the nonresponders.
Conclusion: These results suggest that MHPG level can predict the response to escitalopram